| Intra-articular treatment of knee osteoarthritis: from anti-inflammatories to products of regenerative medicine MM Richards, JS Maxwell, L Weng, MG Angelos, J Golzarian The Physician and sportsmedicine 44 (2), 101-108, 2016 | 212 | 2016 |
| Characterization of umbilical cord blood–derived late outgrowth endothelial progenitor cells exposed to laminar shear stress MA Brown, CS Wallace, M Angelos, GA Truskey Tissue Engineering Part A 15 (11), 3575-3587, 2009 | 110 | 2009 |
| Pluripotent stem cell applications for regenerative medicine MG Angelos, DS Kaufman Current opinion in organ transplantation 20 (6), 663-670, 2015 | 71 | 2015 |
| Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells MG Angelos, PN Ruh, BR Webber, RH Blum, CD Ryan, L Bendzick, ... Blood, The Journal of the American Society of Hematology 129 (26), 3428-3439, 2017 | 68 | 2017 |
| Dynamic adhesion of umbilical cord blood endothelial progenitor cells under laminar shear stress MG Angelos, MA Brown, LL Satterwhite, VW Levering, NT Shaked, ... Biophysical journal 99 (11), 3545-3554, 2010 | 44 | 2010 |
| A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. KA Reiss, Y Yuan, NT Ueno, ML Johnson, S Gill, EC Dees, J Chao, ... Journal of Clinical Oncology 40 (16_suppl), 2533-2533, 2022 | 33 | 2022 |
| Single cell resolution of human hematoendothelial cells defines transcriptional signatures of hemogenic endothelium MG Angelos, JE Abrahante, RH Blum, DS Kaufman Stem Cells 36 (2), 206-217, 2018 | 33 | 2018 |
| Advances in the role of the aryl hydrocarbon receptor to regulate early hematopoietic development MG Angelos, DS Kaufman Current opinion in hematology 25 (4), 273-278, 2018 | 18 | 2018 |
| Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on-and off-rates against non-Hodgkin … Y Zhang, RP Patel, KH Kim, H Cho, JC Jo, SH Jeong, SY Oh, YS Choi, ... Molecular cancer 22 (1), 200, 2023 | 15 | 2023 |
| CD5 deletion enhances the antitumor activity of adoptive T cell therapies RP Patel, G Ghilardi, Y Zhang, YH Chiang, W Xie, P Guruprasad, KH Kim, ... Science Immunology 9 (97), eadn6509, 2024 | 9 | 2024 |
| The BTLA–HVEM axis restricts CAR T cell efficacy in cancer P Guruprasad, A Carturan, Y Zhang, JH Cho, KG Kumashie, RP Patel, ... Nature Immunology 25 (6), 1020-1032, 2024 | 7 | 2024 |
| Progress and pitfalls of chimeric antigen receptor T cell immunotherapy against T cell malignancies MG Angelos, RP Patel, M Ruella, SK Barta Transplantation and Cellular Therapy 30 (2), 171-186, 2024 | 6 | 2024 |
| A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 … Y Abdou, EC Dees, JE Mortimer, PR Pohlmann, ML Johnson, RT Maziarz, ... Journal of Clinical Oncology 41 (16_suppl), TPS2666-TPS2666, 2023 | 6 | 2023 |
| A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with … KA Reiss, Y Yuan, NT Ueno, ML Johnson, S Gill, EC Dees, J Chao, ... Journal of Clinical Oncology 40 (16_suppl), TPS2677-TPS2677, 2022 | 6 | 2022 |
| Advances and personalized approaches in the frontline treatment of T-cell lymphomas MG Angelos, HJ Ballard, SK Barta Journal of Personalized Medicine 12 (2), 267, 2022 | 6 | 2022 |
| Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion JH Kim, AJ Schulte, AL Sarver, D Lee, MG Angelos, AM Frantz, CL Forster, ... Cancer Research Communications 4 (6), 1467-1480, 2024 | 4 | 2024 |
| 633 a phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors K Reiss, N Ueno, Y Yuan, M Johnson, EC Dees, J Chao, M Angelos, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 4 | 2022 |
| Sequence specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin. JL Hays, G Kim, J Mariani, RF Murphy, M Angelos, A McCollum, J Lu, ... Journal of Clinical Oncology 29 (15_suppl), 5025-5025, 2011 | 4 | 2011 |
| A novel function of WW domain binding protein 2 (WBP2) in regulating cytoskeletal function and cellular division through binding to co-chaperone BAG3 AK McCollum, MG Angelos, AD Fischione, M Mineo, EC Kohn Cancer Research 72 (8_Supplement), 2032-2032, 2012 | 3 | 2012 |
| A Phase 1, First-In-Human (FIH) Study of the Anti-HER2 CAR Macrophage CT-0508 in Participants with HER2 Overexpressing Solid Tumors KA Reiss, Y Yuan, NT Ueno, ML Johnson, S Gill, EC Dees, J Chao, ... immunity 1, 2, 0 | 3 | |
